Command Palette

Search for a command to run...

Clinical Trials · NCT00882050

Intravenous Exenatide (Byetta) During Surgery

CompletedPhase 1/Phase 2Exenatide (Approved)
Phase
Phase 1/Phase 2
Recruitment status
Completed
Sponsor
Thomas Jefferson University
Enrollment
104
Start date
Mar 2009
Locations
1 site, United States
Primary endpoint
The Primary Objective is to Determine the Ability of Intravenous Exenatide to: Maintain Intraoperative Euglycemia in Subjects With Initial Blood Glucose < 126 mg/dL in Surgical Subjects as Compared to Placebo,
View Exenatide compound reference